Eyenovia shares are surging Monday in response to the company's announcement of the launch of a new FDA-approved ophthalmic drug in collaboration with Formosa Pharmaceuticals.

Analyst James Wheatcroft of Jefferies maintained a Buy rating on The Gym (GYM – Research Report), retaining the price target of p180.00.

Garmin Ltd.'s Q2 earnings beat expectations with $1.51B in revenue and raised guidance. See why I'm not comfortable starting ...

When my friend told me she was getting divorced I wasn't surprised. What I didn't expect was the grief that I felt through the process. Follow us on: ...